NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive Into Narcolepsy and Idiopathic Hypersomnia
NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive Into Narcolepsy and Idiopathic Hypersomnia
ZURICH, SWITZERLAND / ACCESSWIRE / November 27, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that Alex Zwyer, Chief Executive Officer of NLS Pharmaceutics, will present at the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic Hypersomnia, hosted by Francois Brisebois, Managing Director, Senior Research Biotechnology Analyst, in New York on Friday, December 1, 2023 at 10:30 AM EST.
瑞士蘇黎世/ACCESSWIRE/2023年11月27日/NLS 製藥有限公司（納斯達克股票代碼：NLSP，NLSPW）（“NLS” 或 “公司”）是一家專注於爲罕見和複雜中樞神經系統疾病患者發現和開發創新療法的瑞士臨床階段生物製藥公司，今天宣佈，NLS Pharmaceutics首席執行官亞歷克斯·茲韋爾將出席那個 奧本海默睡眠障礙峯會：深入探討發作性睡病和特發性睡眠過多，由董事總經理兼高級研究生物技術分析師弗朗索瓦·布里塞波依斯於美國東部標準時間2023年12月1日星期五上午10點30分在紐約主持。
Mr. Zwyer will be joining François Brisebois, who will moderate a discussion with leading Key Opinion Leaders in Sleep Medicine, Dr. Edward Mezerhane, MD, FAASM, FACP, Dr. Thomas Stern, MD, and Dr. Michael Thorpy, MD, as well as executives from companies including Avadel Pharmaceuticals, Centessa Pharmaceuticals, Harmony Biosciences, and Zevra Therapeutics.
Zwyer先生將加入弗朗索瓦·布里塞波依斯的行列，後者將主持與睡眠醫學領域主要意見領袖、FAASM、FACP醫學博士愛德華·梅澤哈內博士、醫學博士托馬斯·斯特恩博士和醫學博士邁克爾·索皮博士以及來自阿瓦德爾製藥、森泰薩製藥、和諧生物科學和Zevra Therapeutics等公司的高管的討論。
If you are interested in attending, please contact your Oppenheimer representative.
如果您有興趣參加，請聯繫您的奧本海默代表。
About NLS Pharmaceutics Ltd.
關於 NLS 製藥有限公司
NLS Pharmaceutics Ltd. (Nasdaq: NLSP) is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system, or CNS, disorders, who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit .
NLS Pharmacetics Ltd.（納斯達克股票代碼：NLSP）是一家處於發展階段的全球生物製藥公司，與世界一流的合作伙伴和國際知名的科學家合作，專注於爲醫療需求未得到滿足的罕見覆雜中樞神經系統（CNS）疾病患者發現和開發創新療法。NLS總部位於瑞士，成立於2015年，由經驗豐富的管理團隊領導，他們在開發和商業化候選產品方面有着良好的記錄。欲了解更多信息，請訪問。
For additional information:
欲了解更多信息：
Marianne Lambertson (investors & media)
NLS Pharmaceutics Ltd.
+1 239.682.8500
ml@nls-pharma.com
瑪麗安·蘭伯森（投資者和媒體）
NLS 製藥有限公司
+1 239.682.8500
ml@nls-pharma.com
SOURCE: NLS Pharmaceutics Ltd.
來源：NLS 製藥有限公司